Compare SNCY & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNCY | DRUG |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.5M | 856.4M |
| IPO Year | 2021 | N/A |
| Metric | SNCY | DRUG |
|---|---|---|
| Price | $21.72 | $76.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $19.00 | ★ $106.75 |
| AVG Volume (30 Days) | ★ 2.4M | 125.9K |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,126,769,000.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $8.15 | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $8.10 | $23.18 |
| 52 Week High | $22.12 | $123.75 |
| Indicator | SNCY | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 79.72 | 43.97 |
| Support Level | $16.93 | $72.08 |
| Resistance Level | $18.28 | $81.00 |
| Average True Range (ATR) | 0.69 | 4.85 |
| MACD | 0.16 | -1.57 |
| Stochastic Oscillator | 100.00 | 26.02 |
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.